Collaboration will focus initially on creating a feature in the Flo app to both enable women to monitor for heavy menstrual bleeding and enable research on digital biomarkers for heavy menstrual bleeding
| BASEL, Switzerland and REDWOOD CITY, Calif., Oct. 8, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, and Flo Health, a company developing the world’s fastest growing artificial intelligence (AI)-driven platform for women’s health with 22 million active users, announced today a partnership to create a digital tool to screen for heavy menstrual bleeding. Affecting more than 25 percent of women, heavy menstrual bleeding is associated with diseases such as uterine fibroids and can negatively impact a woman’s quality of life.
“Many women do not know if their menstrual bleeding is normal, and currently there are few tools to evaluate this. By partnering with Flo Health to create a new digital tool embedded in the Flo app, our goal is to help women track their menstrual bleeding so they can identify any concerns and discuss them with a healthcare professional,” said Lynn Seely, M.D., President and CEO of Myovant. “We are pleased to enter into this first-of-its-kind partnership, combining Myovant’s clinical development expertise with Flo’s innovative technology. Our aim is for this initiative to result in important insights and data that will empower women to take a more proactive role in their personal health.” Flo is a women’s health product that encompasses solutions for girls and women at every stage of life (from the onset of menstruation to preparation for pregnancy and motherhood to menopause). Flo uses data science and AI to deliver personalized content and services across 20 languages and is available in iOS and Android. “We developed Flo to be the platform where women can entrust their most intimate health-related concerns. We share Myovant’s mission of empowering women to take charge of their health, including in the area of tracking and better understanding heavy menstrual bleeding,” said Yuri Gurski, Founder and President of Flo. “By partnering with Myovant to create improved digital tools for evaluating and researching periods, we are moving closer to achieving this mission.” About Flo Health About Myovant Sciences Media Contacts: Flo Health
SOURCE Myovant Sciences |
Company Codes: NYSE:MYOV |
View original content to download multimedia:
